Stocktoria
GeoVax Labs, Inc. GOVX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1994-04-04
GeoVax Labs, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.5M | $4.0M | $0 | $81,526 | $385,501 |
| R&D expense | $18.1M | $23.7M | $20.7M | $9.1M | $15.6M |
| Operating income | -$21.6M | -$25.1M | -$26.7M | -$14.0M | -$18.7M |
| Interest expense | — | — | — | $0 | $1,286 |
| Income tax | $0 | — | — | — | $0 |
| Net income | -$21.5M | -$25.0M | -$26.0M | -$14.0M | -$18.6M |
| Operating cash flow | -$21.5M | -$24.7M | -$25.2M | -$19.0M | -$11.2M |
| Free cash flow | -$21.5M | -$24.7M | -$25.2M | -$19.2M | -$11.2M |
| Cash & equivalents | $3.1M | $5.5M | $6.5M | $27.6M | $11.4M |
| Total assets | $6.3M | $8.2M | $9.3M | $31.3M | $11.8M |
| Total liabilities | $2.5M | $3.1M | — | $4.7M | $7.4M |
| Shareholders' equity | $3.8M | $5.0M | $5.8M | $26.6M | $4.4M |
Source: SEC EDGAR filings · CIK 0000832489 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.